Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Kioumis, P. Zarogoulidis, S. Lampaki, J. Organtzis, L. Yarmus, J. F. Turner, K. Zarogoulidis, G. Pitsiou, A. Pataka, R. Browning (Thessaloniki, Baltimore, Greece; Las Vegas, Bethesda, United States Of America). Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid). Eur Respir J 2014; 44: Suppl. 58, 4697

Member's Comments

No comment yet.

Related content which might interest you: Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Bactericidal activity of ciprofloxacin dry powder for inhalation (DPI) in a hollow fiber (HF) model Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Effect of N-acetylcysteine on the activity of antibiotics against relevant respiratory pathogens Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Monitoring of antimicrobial resistance respiratory strains of streptococcus pneumoniae Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 High carbapenem resistance in gram negative bacterial isolates: An outcome study Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 Antibiotics to treat Community-acquired Lower Respiratory Tract Infections: mechanism of action, spectrum, epidemiology resistance. Source: Value-Dx event 2019: VALUE-Dx kick off meeting and course Year: 2019 Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Factors affecting treatment success in community acquired pneumonia (CAP) Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 High prevalence of resistant bacterial infections in patients with tracheostomy due to neuromuscular disease (NMD) Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Extended-spectrum-beta-lactamase producing multidrug resistant nosocomial bacterial isolates causing lower respiratory tract infection in Tertiary Care Hospital, Nepal Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Parachlamydia acanthamoebae as a respiratory pathogen: Challenge dose titration in a bovine model Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 The impact of mixed etiology in community acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Influence of long antibiotic therapy of lower respiratory tract infection (LRTI) on cytological characteristics of sputum Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016